Shots:

• Neurimmune to receive an up front, research fees & is eligible to receive milestones on the research and development progress along with royalties on product sales. Additionally, both companies focus to generate and validate human-derived mAb against Ono’s newly selected drug targets by using Neurimmune’s reverse translational medicine (RTM) technology platform
• Ono will obtain exclusive rights for the development and commercialization globally of antibody products that emerge from the collaboration
• In Nov 2017, Ono entered into a collaboration with Neurimmune to identify and develop human Abs using the RTM technology platform

Ref: Neurimmune | Image: PR Newswire